ChromaDex (CDXC) Competitors

ChromaDex (NASDAQ:CDXC) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.

Which has better valuation & earnings, CDXC or TVTX?

ChromaDex has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ChromaDex	$83.57M	4.95	-$4.94M	$0.01	542.54
Travere Therapeutics	$203.45M	8.43	-$111.40M	-$4.55	-4.83

Does the MarketBeat Community prefer CDXC or TVTX?

ChromaDex received 462 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 64.50% of users gave ChromaDex an outperform vote while only 58.87% of users gave Travere Therapeutics an outperform vote.

Company	Underperform	Outperform
ChromaDex	Outperform Votes 545 64.50%	Underperform Votes 300 35.50%
Travere Therapeutics	Outperform Votes 83 58.87%	Underperform Votes 58 41.13%

Which has more volatility and risk, CDXC or TVTX?

ChromaDex has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.

Does the media prefer CDXC or TVTX?

In the previous week, Travere Therapeutics had 9 more articles in the media than ChromaDex. MarketBeat recorded 12 mentions for Travere Therapeutics and 3 mentions for ChromaDex. ChromaDex's average media sentiment score of 0.54 beat Travere Therapeutics' score of 0.06 indicating that ChromaDex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ChromaDex	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do analysts prefer CDXC or TVTX?

ChromaDex currently has a consensus price target of $8.00, suggesting a potential upside of 47.60%. Travere Therapeutics has a consensus price target of $27.77, suggesting a potential upside of 26.34%. Given ChromaDex's stronger consensus rating and higher possible upside, equities research analysts plainly believe ChromaDex is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ChromaDex	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Travere Therapeutics	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Is CDXC or TVTX more profitable?

ChromaDex has a net margin of 1.62% compared to Travere Therapeutics' net margin of -172.75%. ChromaDex's return on equity of 4.85% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ChromaDex	1.62%	4.85%	2.70%
Travere Therapeutics	-172.75%	-537.74%	-55.65%

Do insiders and institutionals have more ownership in CDXC or TVTX?

15.4% of ChromaDex shares are held by institutional investors. 9.6% of ChromaDex shares are held by insiders. Comparatively, 3.8% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ChromaDex beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks.